Abeona Posts $8.7 Million Q1 From ZEVASKYN as Patient Treatments and Sites Expand

Overview

• Abeona reported $8.7 million in first‑quarter net product revenue from three ZEVASKYN treatments, following one treatment in late 2025 and one so far in the current quarter.
• Five patients have now received the therapy, with a sixth in manufacturing and six more biopsies expected this quarter, four already scheduled.
• The company has six qualified treatment centers active and plans to add a seventh this year, with more than 100 potential patients identified and payer coverage reaching 95% of commercially insured lives.
• ZEVASKYN is a personalized cell therapy for recessive dystrophic epidermolysis bullosa, a rare and severe skin disease, which makes insurance approval and treatment‑center capacity crucial for timely care.
• Abeona licensed a PSMA‑directed T‑cell therapy for prostate cancer called ABO‑701, expects a pre‑IND meeting with the FDA in June 2026, targets first‑in‑human studies in the second half of 2027, and says near‑term R&D spend stays low with $168.3 million in cash on hand.